• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- National Association of Corporate Directors/

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $BIIB alert in real time by email

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows:

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence

    WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately.

    The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape.

    Mantas serves on the boards of Biogen (NASDAQ:BIIB), where he chairs the compensation and management development committee, and International Flavors & Fragrances (NYSE:IFF), where he is on the innovation and audit committees. He is a Senior Advisor for NASDAQ, the Council for Global Competition and Innovation and IE University New York College and is vice chair of the board of HITEC. Mantas recently retired as the global leader of IBM Business Transformation Services.

    "I am honored to follow my mentor and fellow IBM senior leader Nick Donofrio as I join the NACD board," Mantas said. "As directors, we face compounding geopolitical, generational and technological disruption in the companies and communities we serve. I look forward to working with the NACD board and the broader corporate governance ecosystem to steward sustainable value creation in the global boardrooms we serve."

    Bricker brings together the combined impact of 134,000 Assurance partners and staff across the PwC network. He helps guide the development of trust, transparency and value creation for companies and investors through innovative, high-quality assurance solutions. Previously, he served as PwC U.S. vice chair and Trust Solutions co-leader, leading the firm's audit, digital assurance and tax reporting practices. Earlier, Bricker was chief accountant of the U.S. Securities and Exchange Commission. He also serves on the board of the American Institute of Certified Professional Accountants (AICPA) and as chair of the board of XBRL International.

    "NACD plays a critical role in elevating board performance and advancing trust in the capital markets," Bricker said. "I'm honored to join the NACD board and contribute to its work in strengthening governance, transparency and board-management alignment."

    Peter Gleason, president and CEO of NACD, welcomed both leaders to the board.

    "Jesús and Wes each bring exceptional insight and experience that reflect the dynamic needs of today's boards," Gleason said. "Jesús' expertise in digital transformation and innovation, combined with Wes' deep understanding of regulatory, legal and audit issues, will be invaluable as NACD continues to equip boards to lead with purpose and confidence."

    Mantas holds degrees in telecommunications and business administration from the Universidad Politécnica de Madrid and has served as an adjunct professor at the University of California Graduate School of Management and is certified in Corporate Governance by Harvard Business School. Bricker is a certified public accountant licensed in Virginia, Pennsylvania, New Jersey and the District of Columbia, and is a member of the New York State Bar Association.

    Visit the NACD Governance web page to learn more. 

    About NACD

    The National Association of Corporate Directors® (NACD®) is the leading member organization for corporate directors who want to expand their knowledge, grow their network and maximize their potential. For more than 47 years, NACD has helped boards and the business community elevate their performance and create long-term value. Our leadership continues to raise standards of excellence and advance board effectiveness at thousands of member companies.

    NACD's value insights, professional development events and resources, such as the NACD Directors Summit™ and the NACD Directorship Certification® program, support boards in navigating complex challenges. With a growing network of more than 24,000 members across more than 20 Chapters, boards are better equipped to make well-informed decisions on the critical, strategic issues facing their businesses today. Learn more at www.nacdonline.org.

    Press Contact: 

    Shannon Bernauer 

    sbernauer@nacdonline.org

    571-367-3688

    (PRNewsfoto/National Association of Corporate Directors)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/global-leaders-jesus-mantas-and-wes-bricker-join-nacd-board-of-directors-302580855.html

    SOURCE National Association of Corporate Directors

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $IFF

    CompanyDatePrice TargetRatingAnalyst
    Biogen Inc.
    $BIIB
    7/13/2026$235.00Hold → Buy
    Truist
    Biogen Inc.
    $BIIB
    6/8/2026$255.00Hold → Buy
    Needham
    Biogen Inc.
    $BIIB
    5/15/2026Outperform
    Evercore ISI
    Biogen Inc.
    $BIIB
    4/22/2026$225.00Neutral → Buy
    UBS
    Biogen Inc.
    $BIIB
    4/20/2026$250.00Equal Weight → Overweight
    Wells Fargo
    Biogen Inc.
    $BIIB
    4/14/2026$214.00Neutral → Overweight
    Piper Sandler
    Biogen Inc.
    $BIIB
    2/20/2026$185.00Equal Weight
    Barclays
    International Flavors & Fragrances Inc.
    $IFF
    2/13/2026$97.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $BIIB
    $IFF
    SEC Filings

    View All

    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - BIOGEN INC. (0000875045) (Filer)

    7/1/26 4:08:37 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 11-K filed by International Flavors & Fragrances Inc.

    11-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    6/29/26 4:47:07 PM ET
    $IFF
    Major Chemicals
    Industrials

    International Flavors & Fragrances Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    6/23/26 4:39:50 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SuanNutra, a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF

    MADRID, July 20, 2026 /PRNewswire/ -- SuanNutra, a global provider of science-backed branded and functional ingredients, and Carbyne Equity Partners today announced that SuanNutra has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE:IFF). The businesses will merge with SuanNutra's existing operations to create an enlarged global group in science-backed natural ingredients. The transaction is expected to complete by the end of 2026, subject to regulatory clearances and customary closing conditions. Positioned to be a new category leaderThe combination is a transformational ste

    7/20/26 8:01:00 AM ET
    $IFF
    Major Chemicals
    Industrials

    IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.

    IFF (NYSE:IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. "These businesses are highly respected, and we are confident they will conti

    7/20/26 6:45:00 AM ET
    $IFF
    Major Chemicals
    Industrials

    Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

    Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with Biogen Inc. (NASDAQ:BIIB) to support disease education

    7/16/26 7:47:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    6/11/26 5:50:34 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    6/11/26 5:47:54 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    6/11/26 5:46:22 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biogen upgraded by Truist with a new price target

    Truist upgraded Biogen from Hold to Buy and set a new price target of $235.00

    7/13/26 8:58:02 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by Needham with a new price target

    Needham upgraded Biogen from Hold to Buy and set a new price target of $255.00

    6/8/26 8:21:53 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI resumed coverage on Biogen

    Evercore ISI resumed coverage of Biogen with a rating of Outperform

    5/15/26 8:16:23 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $20,317,854 worth of shares (273,500 units at $74.29), increasing direct ownership by 46% to 43,150 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    6/2/26 5:22:26 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director Fribourg Paul J bought $10,971,329 worth of shares (156,459 units at $70.12) and sold $14,481 worth of shares (222 units at $65.23), increasing direct ownership by 92% to 29,650 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $995,204 worth of shares (14,260 units at $69.79), increasing direct ownership by 18% to 91,630 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:47 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    Submission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Leadership Updates

    Live Leadership Updates

    View All

    Biogen Appoints Michael J. Parini as Chief Legal Officer

    CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions. "Michael brings to Biogen a rare combination of deep legal and industry expertise as well as broad operational leadership that will further contribute to Biogen’s next chapter of renewed growth," said Christopher A. Viehbacher, President and Chief Executive O

    7/15/26 8:15:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

    –Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R

    7/13/26 7:30:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

    NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE:BFAM) will replace Tri Pointe Homes Inc. (NYSE:TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take

    5/7/26 6:01:00 PM ET
    $APLS
    $BFAM
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Consumer Discretionary

    $BIIB
    $IFF
    Financials

    Live finance-specific insights

    View All

    IFF to Release Second Quarter 2026 Results on August 4, 2026

    IFF (NYSE:IFF) today announced that it will release its second quarter 2026 earnings results following the market close on Tuesday, August 4, 2026. The management team will host a live webcast on Wednesday, August 5, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovatin

    7/9/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care